VIKRAM MEHRA: Open Payments
NPI 1801848957 · KATY, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$186,839 in 441 payments from 16 companies in 2025. Trend: 2023 $246,422 · 2024 $278,368 · 2025 $186,839
Speaker / faculty: $145,930Consulting: $17,705Travel & lodging: $15,162Food & beverage: $7,967Education: $76
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 154 | $77,971 |
| Alkermes, Inc. | 95 | $54,707 |
| Teva Pharmaceuticals USA, Inc. | 74 | $40,520 |
| Otsuka America Pharmaceutical, Inc. | 44 | $10,660 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $1,620 |
| Vanda Pharmaceuticals Inc. | 15 | $332 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $287 |
| ABBVIE INC. | 18 | $259 |
| Lundbeck LLC | 6 | $138 |
| Janssen Pharmaceuticals, Inc | 4 | $110 |
Products named: COBENFY, LYBALVI, UZEDY, AUSTEDO XR, REXULTI, ABILIFY ASIMTUFII, ARISTADA, FANAPT.
Industry payments across TX — which companies pay providers there.
